Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431208 | 0.93 | MAPT (0.36) | GRM4RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL2433596 | 0.89 | MAPT (0.36) | GRM4RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL2428555 | 0.89 | GRM4 (0.31) | GRM4 | |
| SCHEMBL2430852 | 0.87 | GRM4 (0.44) | GRM4RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL2430579 | 0.87 | GRM4 (0.44) | GRM4RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL2432741 | 0.85 | RAB9A (0.42) | GRM4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2432736 | 0.85 | RAB9A (0.42) | GRM4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2430364 | 0.84 | NPC1 (0.40) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2431179 | 0.83 | KDM4E (0.35) | RAB9ASMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL2429131 | 0.82 | GRM4 (0.33) | GRM4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | claimed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | claimed |
| EP-2086966-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SmithKline Beecham Corporation (US) | 2009-08-12 | — | — | EP | claimed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | claimed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| EP-2086966-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SmithKline Beecham Corporation (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | GRM4 3141/4885RAB9A 2071/4885NPC1 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.